
BTK-Inhibitor Development: A Researcher's Perspective
Healthcare Unfiltered
00:00
I'm Incompetent in the Lab, I'll Run an Experiment to Save My Life
Jeffrey Levy: I had never really competently worked in the lab, and I realized only route to pursue this idea was to go ask if Ron would let me do it. But we scrap together enough rudimentary data, you know, to sort of validate the hypothesis. And so all three of us ended up cold calling Rigel pharmaceuticals for this sick inhibitor within several months of each other. We were seeing responses in follicular lymphoma. You know, they weren't stunning responses, but biologically you knew something was happening. Then we saw this really unusual signal in CLL and SLL, where we would get this,. you know, pronounced lymphocytosis with shrinkage of lymph
Transcript
Play full episode